Dihexa

Dihexa is a relatively new drug that has been synthesized for the purpose of treating Alzheimer’s Disease. Developed by researchers from Washington State University, Dihexa has been shown to bolster cognitive function in lab rats with an Alzheimer-like mental disorder. It is extremely popular among the medical community thanks to its unique approach to the disease; whereas most Alzheimer’s drugs impede the progression of the disease, Dihexa repairs the damage in the synapse between neurons.

Researchers Harding and Wright worked tirelessly to develop the drug from the 90’s on. By 2012, they had found a way for their compound to cross the blood-brain barrier. Although the FDA has yet to approve Dihexa, Harding and Wright’s hard work has already been vindicated courtesy of the nootropic community’s enthusiasm for and support of the drug.

Dihexia, or Dihexa, as it is more commonly known, has been called a “neurogenic wonder-drug” by Nootropix.com. In their comprehensive review of the substance, the drug was said to be ten million times stronger than BDNF, one of the leading medications for new synapse formation.

The specific mechanisms of Dihexa are still nebulous at best and little information about the drug is available online or in medical journals. This much is clear: Harding and Wright discovered this wonder-drug’s properties quite by accident. In the course of their usual experimentation into ACE inhibitors and the like, they stumbled upon a sequence of angiotensin that didn’t induce the hypertensive effects of its predecessors. Further exploration found that said angiotensin (Angiotensin IV) pooled inside the hippocampus portion of the brain. This lead to the hypothesis that there was a correlation between Angiotensin IV and memory formation.

Armed with a pharmacological grant from the company behind such drugs as Cymbalta and Prozac, Harding and his team were able to develop a multitude of Angiotensin IV analogues for further testing. His hard work parlayed itself into miraculous findings; Ang-IV, as it is known in short form, was able to reverse all impairment across multiple cognitive models of decline.

Unfortunately for Harding and Co., funding was pulled when the above-mentioned company was plunged into scandal for failing to warn patients of the potential risks of birth defects when taking Prozac. Lawsuits followed and the project was shelved . Testing wouldn’t resume for some time.

In the early-Aughts, the project was picked up and dusted off. It was then that Harding narrowed in on the particular peptides requisite to the precognitive properties of a specific analogue in their experimentation. The analogue, known as Nle-Angiotensin-IV, was altered and a tripeptide sequence was concocted. Additional modification was undertaken and, after some time, they had the analogue now referred to as Dihexa (MM-201).

The dimerization process of Dihexa is behind the management of proteins which bind with DNA strands. The growth factor in its activated form yields increased HGF activity and diminishes dimerization. HGF activity, or Hepatocyte Growth Factor, stimulates DNA synthesis and builds up an uptake of hepatocytes, cells that are involved in protein synthesis. Dimerization is a macromolecular complex. HGF activity is responsible for synaptogenic and procognitive activities.

In addition to Alzheimer’s, Dihexa has been used to manage depression, improve general long and short-term memory, focus and learning. That said, its primary reputation is as a potent nootropic supplement for those afflicted with AD. It has also been considered as a prospective guard against aminoglycoside toxicity in hair cells.  The outcome of this test found that Dihexa provided optimal protection against severe treatment with otoxin.

Although Dihexa seems to have a wealth of benefits, it isn’t without its adverse effects. One Reddit user reports side effects that seem to preclude it from being an eligidible candidate for regular use. After a one-week trial, said user had this to say about their experience on Dihexa:

“The biggest problem was the mounting attention deficit, which mirrored the complications exhibited by extended NSI-189 supplementation. I couldn’t gauge whether this side effect aggregated distinctly faster with Dihexa than it does with NSI-189–which seemed to get to its worst at around 4 weeks of continuous use–but it seemed to be getting there when I decided to stop.

“Also, on the days I wasn’t dosing the URB-597, I consistently had difficulties with irritability and other forms of hyperemotionality; it’s funny to say, but both URB and cannabis seemed to drastically increase the benefits of this drug, due to the mood stabilization and creativity promotion of these drugs, respectively, and the combination of a cannabinergic with Dihexa was, to quote my earlier expression to a friend, ‘like Phenibut and NSI-189 had a precocious child.’”

Some websites that offer Dihexa solutions explicitly ask the buyer to indemnify them from any liability with regard to adverse effects. From what little evidence available on the Web, the one clear side effect relates to withdrawal after discontinuing use. Jitters and irritability are, apparently, the norm, though no known reports of more acute withdrawal symptoms can be dug up at this time. This is good news for nootropic enthusiasts who want to avoid the cardiac and respiratory issues associated with detoxing from other mind-boosting supplements.

The general consensus among the nootropic community at large suggests that there are no significant contraindications with Dihexa.

The average dosages are between eight and forty-five milligrams taken orally by dropper with some users vaping it. As with almost all supplements, users should consult with their physician if they are pregnant, nursing or taking prescription drugs on a daily basis.